{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+Control&page=8",
    "query": {
      "intervention": "Vehicle Control",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 1096,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+Control&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+Control&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T19:32:43.132Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01528111",
      "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "LX7101 (0.125%)",
          "type": "DRUG"
        },
        {
          "name": "LX7101 (0.25%)",
          "type": "DRUG"
        },
        {
          "name": "LX7101 Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2012-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2015-09-14",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 5,
      "location_summary": "Morrow, Georgia • Memphis, Tennessee • Austin, Texas + 2 more",
      "locations": [
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528111"
    },
    {
      "nct_id": "NCT05244980",
      "title": "A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alopecia, Androgenetic"
      ],
      "interventions": [
        {
          "name": "TDM-105795",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Technoderma Medicines Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2022-02-01",
      "completion_date": "2023-02-27",
      "has_results": false,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 2,
      "location_summary": "San Diego, California • College Station, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05244980"
    },
    {
      "nct_id": "NCT00353964",
      "title": "Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ocular Inflammation"
      ],
      "interventions": [
        {
          "name": "rEV131",
          "type": "DRUG"
        },
        {
          "name": "Prenisolone sodium phosphate 1.0%",
          "type": "DRUG"
        },
        {
          "name": "rEV131 vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Evolutec Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-28",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 1,
      "location_summary": "North Andover, Massachusetts",
      "locations": [
        {
          "city": "North Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00353964"
    },
    {
      "nct_id": "NCT00919763",
      "title": "Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "CD2027 Ointment 3 mcg/g, twice daily",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Ointment, twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2009-05-21",
      "completion_date": "2009-10-01",
      "has_results": true,
      "last_update_posted_date": "2022-07-19",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 14,
      "location_summary": "Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00919763"
    },
    {
      "nct_id": "NCT00847912",
      "title": "CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Carcinoma, Basal Cell",
        "Carcinoma, Squamous Cell",
        "Skin Neoplasms",
        "Skin Diseases",
        "Neoplasms, Basal Cell",
        "Neoplasms, Squamous Cell",
        "Carcinoma"
      ],
      "interventions": [
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Placebo, vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 954,
      "start_date": "2009-06-26",
      "completion_date": "2016-07-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 13,
      "location_summary": "Palo Alto, California • San Diego, California • Denver, Colorado + 10 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00847912"
    },
    {
      "nct_id": "NCT01145807",
      "title": "TDT 067 Onychomycosis Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Onychomycosis"
      ],
      "interventions": [
        {
          "name": "TDT067",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Transfersome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celtic Pharma Development Services",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 738,
      "start_date": "2010-04",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 1,
      "location_summary": "Albequerque, New Mexico",
      "locations": [
        {
          "city": "Albequerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01145807"
    },
    {
      "nct_id": "NCT05593432",
      "title": "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Lichen Planus"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2022-11-23",
      "completion_date": "2024-02-26",
      "has_results": true,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05593432"
    },
    {
      "nct_id": "NCT02611804",
      "title": "A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Diclofenac sodium",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 492,
      "start_date": "2015-10",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2017-05-05",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 30,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611804"
    },
    {
      "nct_id": "NCT01670032",
      "title": "Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Impetigo"
      ],
      "interventions": [
        {
          "name": "Experimental: CD07223 1.5 % Topical Gel BID",
          "type": "DRUG"
        },
        {
          "name": "Experimental: CD07223 1.5% Topical Gel TID",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: CD07223 vehicle gel BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: CD07223 vehicle gel TID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NovaBay Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2012-08",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-08-12",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 7,
      "location_summary": "Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more",
      "locations": [
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Gresham",
          "state": "Oregon"
        },
        {
          "city": "Cheraw",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670032"
    },
    {
      "nct_id": "NCT04867434",
      "title": "Efficacy and Safety of RZL-012 on Submental Fat Reduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Submental Fat"
      ],
      "interventions": [
        {
          "name": "RZL-012",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Raziel Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 151,
      "start_date": "2021-06-15",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-19T19:32:43.132Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04867434"
    }
  ]
}